Suicide Gene/Prodrug therapy for pancreatic adenocarcinoma by E. coli purine nucleoside phosphorylase and 6-methylpurine 2′-deoxyriboside

Pancreas

Volumn 28, Issue 2, 2004, Pages

  Deharvengt, Sophie ^a   Wack, Séverine ^a   Aprahamian, Marc ^a   Hajri, Amor ^a  

^a INSERM   (France)

Author keywords

Escherichia coli purine nucleoside phosphorylase; Gene therapy; Pancreatic cancer; Suicide gene

Indexed keywords

6 METHYLPURINE 2' DEOXYRIBOSIDE; 6-METHYLPURINE 2'-DEOXYRIBOSIDE; ANTINEOPLASTIC AGENT; PRODRUG; PURINE NUCLEOSIDE; PURINE NUCLEOSIDE PHOSPHORYLASE;

ADENOCARCINOMA; ANIMAL; APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CELL JUNCTION; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; ESCHERICHIA COLI; FEMALE; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; MOUSE; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; SUICIDE TRANSGENE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BYSTANDER EFFECT; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; ESCHERICHIA COLI; FEMALE; GAP JUNCTIONS; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HUMANS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PRODRUGS; PURINE NUCLEOSIDES; PURINE-NUCLEOSIDE PHOSPHORYLASE; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 4444281856     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/00006676-200403000-00020     Document Type: Article

References (48)

1. Ahrendt SA, Pitt HA. Surgical management of pancreatic cancer. Oncology (Huntingt). 2002; 16:725-734.
2. Beger HG, Gansauge F, Leder G. Pancreatic cancer: who benefits from curative resection? Can J Gastroenterol. 2002; 16:117-120.
3. Johnson C. Prognosis in pancreatic cancer. Lancet. 1997; 349:1027-1028.
4. Fernandez-Cruz L, Johnson C, Dervenis C. Locoregional dissemination and extended lymphadenectomy in pancreatic cancer. Dig Surg. 1999; 16:313-319.
5. Bramhall SR, Neoptolemos JP. Adjuvant chemotherapy in pancreatic cancer. Int J Pancreatol. 1997; 21:59-63.
6. Graziano F, Catalano G, Cascinus S. Chemotherapy for advanced pancreatic cancer: the history is changing. Tumori. 1998; 84:308-311.
7. Spanknebel K, Conlon KC. Advances in the surgical management of pancreatic cancer. Cancer J. 2001; 7:312-323.
8. Lu Z, Kleef J, Shrikhande S, et al. Expression of the multidrug resistance 1 (MDR1) gene and prognosis in human pancreatic cancer. Pancreas. 2000; 21:240-247.
9. Kasuya H, Nomoto S, Kimata H, et al. Gene therapy for pancreatic cancer. Hepatogastroenterology. 2001; 48:957-961.
10. Gilliam AD, Watson SA. Emerging biological therapies for pancreatic carcinoma. Eur J Surg Oncol. 2002; 28:370-378.
11. Aoki K, Yoshida T, Matsumoto N, et al. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther. 1997; 8:1105-1113.
12. Martiniello-Wilks R, Garcia-Aragon J, Daja MM, et al. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum Gene Ther. 1998; 9:1617-1626.
13. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes paradigm for a prospective cancer control strategy. Cancer Res. 1986; 46:5276-5281.
14. Moolten FL, Vonderhaar BK, Mroz PJ. Transduction of the herpes thymidine kinase gene into premalignant murine mammary epithelial cells renders subsequent breast cancers responsive to ganciclovir therapy. Hum Gene Ther. 1996; 7:1197-1204.
15. Greco E, Fogar P, Basso D, et al. Retrovirus-mediated herpes simplex virus thymidine kinase gene transfer in pancreatic cancer cell lines: an incomplete antitumor effect. Pancreas. 2002; 25:21-29.
16. Aghi M, Hochberg F, Breakefield XO. Prodrug activation enzymes in cancer gene therapy. J Gene Med. 2000; 2:148-164.
17. Huber BE, Austin EA, Richards CA, et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A. 1994; 91:8302-8306.
18. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002; 62:4968-4976.
19. Chung-Faye GA, Chen MJ, Green NK, et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther. 2001; 8:1547-1554.
20. Kuriyama S, Masui K, Sakamoto T, et al. Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. Anticancer Res. 1998; 18:3399-3406.
21. Kievit E, Nyati MK, Ng E, et al. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res. 2000; 60:6649-6655.
22. Elshami AA, Saavedra A, Zhang H, et al. Gap junctions play a role in the "bystander effect" of the herpes virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 1996; 3:85-92.
23. Qiao J, Black ME, Caruso M. Enhanced ganciclovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant. Hum Gene Ther. 2000; 11:1569-1576.
24. Kim YG, Bi W, Feliciano ES, et al. Ganciclovir-mediated cell killing and bystander effect is enhanced in cells with two copies of the herpes simplex virus thymidine kinase gene. Cancer Gene Ther. 2000; 7:240-246.
25. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res. 2000; 60:3989-3999.
26. Sorscher EJ, Peng S, Bebock Z, et al. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther. 1994; 1:233-238.
27. Park BJ, Brown CK, Hu Y, et al. Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. Hum Gene Ther. 1999; 10:889-898.
28. Bzowska A, Kulikowska E, Shugar D. Purine nucleoside phosphorylases: properties, functions, and clinical aspects. Pharmacol Ther. 2000; 88:349-425.
29. Lee J, Filosa S, Bonvin J, et al. Expression, purification, and characterization of recombinant purine nucleoside phosphorylase from Escherichia coli. Protein Expres Purif. 2001; 22:180-188.
30. Mao C, Cook WJ, Zhou M, et al. The crystal structure of Escherichia coli purine nucleoside phosphorylase: a comparison with the human enzyme reveals a conserved topology. Structure. 1997; 5:1373-1383.
31. Hughes BW, King SA, Allan PW, et al. Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase. J Biol Chem. 1998; 273:2322-2328.
32. Krohne TU, Shankara S, Geissler M, et al. Mechanisms of cell death induced by suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma cells in vitro. Hepatology. 2001; 34:511-518.
33. Hughes BW, Wells AH, Bebok Z, et al. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylases gene. Cancer Res. 1995; 55:3339-3345.
34. Parker WB, King SA, Allan PW, et al. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylases. Hum Gene Ther. 1997; 8:1637-1644.
35. Gadi VK, Alexander SD, Kudlow JE, et al. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylases in a small fraction of cells. Gene Ther. 2000; 7:1738-1743.
36. Martiniello-Wilks R, Garcia-Aragon J, Daja MM, et al. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum Gene Ther. 1998; 9:1617-1626.
37. Voeks D, Martiniello-Wilks R, Madden V, et al. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther. 2002; 9:759-768.
38. Pettengill OS, Faris RA, Bell Jr., RH et al. Derivation of ductlike cell lines from a transplantable acinar cell carcinoma of the rat pancreas. Am J Pathol. 1993; 143:292-303.
39. Touraine RL, Vahanian N, Ramsey WJ, et al. Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum Gene Ther. 1998; 9:2385-2391.
40. Hajri A, Coffy S, Vallat F, et al. Human pancreatic carcinoma cells are sensitive to photodynamic therapy in vitro and in vivo. Br J Surg. 1999; 86:899-906.
41. Curiel DT, Gerritsen WR, Krul MR. Progress in cancer gene therapy. Cancer Gene Ther. 2000; 7:1197-1199.
42. Halloran CM, Ghaneh P, Neoptolemos JP, Costello E. Gene therapy for pancreatic cancer-current and prospective strategies. Surg Oncol. 2000; 9:181-191.
43. Kellen JA. Gene therapy in cancer. J Exp Ther Oncol. 2002; 2:312-316.
44. Boucher PD, Ruch RJ, Shewach DS. Differential ganciclovir-mediated cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase. Hum Gene Ther. 1998; 9:801-814.
45. Chung-Faye GA, Chen MJ, Green NK, et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther. 2001; 8:1547-1554.
46. Springer CJ, Niculescu-Duvaz I. Prodrug-activating systems in suicide gene therapy. J Clin Invest. 2000; 105:1161-1167.
47. Touraine RL, Ishii-Morita H, Ramsey WJ, et al. The bystander effect in the HSV-tk/ganciclovir system and its relationship to gap junctional communication. Gene Ther. 1998; 5:1705-1711.
48. Robe PA, Princen F, Martin D, et al. Pharmacological modulation of the bystander effect in the herpes simplex virus thymidine kinase/ganciclovir gene therapy system: effects of dibutyryl adenosine 3′,5′-cyclic monophosphate, α-glycyrrhetinic acid, and cytosine arabinoside. Biochem Pharmacol. 2000; 60:241-249.